<DOC>
	<DOCNO>NCT00003026</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Hormone therapy use triptorelin may fight prostate cancer reduce production androgen . PURPOSE : Randomized phase III trial compare effectiveness long-term hormone therapy triptorelin treatment treat patient advanced prostate cancer previously treat radiation therapy 6 month androgen suppression .</brief_summary>
	<brief_title>Hormone Therapy Treating Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine best hormonal scheme associate pelvic radiotherapy curative management prostatic carcinoma hormonal treatment regard treatment outcome ( overall survival , clinical disease free survival , local regional control ) , quality life ( treatment side effect , sexual function ) , health economy ( cost effectiveness ratio ) . OUTLINE : This randomize , multicenter study . Patients receive external radiation 5 week , follow pelvic boost give 2 week 6 month combine androgen blockage initiate onset external irradiation . Flutamide ( Eulexin ) bicalutamide ( Casodex ) may use antiandrogens . Antiandrogen treatment start 1 week first injection triptorelin . Patients randomize one two treatment arm . - Arm I : Patients receive treatment . - Arm II : Patients receive antiandrogen 2.5 year plus LHRH analogue ( triptorelin ) administer every 3 month . Patients continue LHRH analogue alone additional 2.5 year absence disease progression . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 966 patient accrue 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate T1cT2ab , N12 pN12 ( pelvic lymphadenectomy ) T2cT4 , N02 Prior external radiotherapy locally advance prostatic carcinoma require Prior hormone therapy ( 6 month combine androgen blockade ) locally advanced prostatic carcinoma require PSA great 150 ng/mL administration No progressive disease 6 month combine androgen blockage No stag T1c/T2ab negative pelvic lymph node status assess clinically surgically No lymph node involvement common iliac and/or periaortic lymph node ( M1a ) No external iliac lymph node metastasis 5 cm great dimension ( N3 ) No distant metastasis PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Life expectancy : At least 5 year Hematopoietic : Hemoglobin least 10 g/dL WBC least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Not specify Other : No prior concurrent cancer basal cell skin cancer No serious nonmalignant disease result life expectancy le 5 year PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy prostate cancer Chemotherapy No prior chemotherapy prostate cancer Endocrine therapy See Disease Characteristics Radiotherapy See Disease Characteristics Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>